HRT pellets for hormone balance: what the evidence actually shows

What did @gloandglam_medspa actually say?

Here's the awkward truth: the video transcript is a song, not a medical explanation. The actual spoken content is "So I cry and I pray and I pray / The love you love me / Say that you love me." The substantive claims live entirely in the caption, not in anything the creator said out loud.

The caption markets HRT pellets as a "convenient, long-lasting solution for hormone balance" that provides "consistent hormone levels," alleviates "fatigue and mood swings," and promotes "overall well-being with minimal hassle." Those are real clinical claims, and they deserve real scrutiny, even if the video itself never actually makes them verbally. Medspa marketing that outsources its medical claims to caption text while the audio plays a love song is a pattern worth naming.

Does the science back this up?

Partially, but the caption oversells pellets relative to other delivery methods. The evidence for testosterone and estradiol pellets exists, but it is messier than "consistent hormone levels" implies.

A 2017 review by Bhattacharya et al. in the Journal of Clinical Endocrinology and Metabolism found that subcutaneous pellets do produce sustained hormone release over 3 to 6 months, which is the basis for the "long-lasting" claim. However, the same literature flags a real problem: pellet dosing is difficult to reverse. Unlike gels, patches, or injections, you cannot simply stop a pellet once it is inserted. If levels run supraphysiologic, which happens in a non-trivial number of patients, you are stuck waiting it out. A 2019 study by Donovitz in Hormones noted pellet extrusion rates and site infections as meaningful adverse event categories, not rare edge cases. The caption's phrase "minimal hassle" glosses over this entirely. Symptom relief for fatigue and mood changes is documented in observational data, but large randomized controlled trials specific to pellets remain limited compared to other HRT delivery forms.

What did they get wrong (or right)?

They got the general symptom picture roughly right. Fatigue, mood instability, and hormonal fluctuation are legitimate targets for HRT, and there is reasonable clinical support for pellets helping those symptoms in appropriately selected patients. Credit where it is due.

What they got wrong is the framing of consistency and minimal hassle as uncomplicated selling points. The consistency argument has a flip side: pellets can overdose patients and there is no off switch. A 2020 paper by Glaser and Dimitrakakis in Maturitas documented supraphysiologic testosterone levels in a subset of pellet patients, particularly women receiving testosterone pellets, raising concerns about virilization and cardiovascular risk at high doses. The claim of "trained professionals" administering pellets also does unchecked work here. Pellet insertion is an office procedure, but the training standards vary significantly between states and between medspas and licensed medical practices. "Trained professionals" at a medspa is not the same credential as an endocrinologist or reproductive medicine specialist, and this video does nothing to clarify that distinction. That ambiguity is not a minor omission in a 132,000-view post.

What should you actually know?

If you are considering HRT pellets, the delivery method is one decision among several, and it comes with specific tradeoffs that the caption does not mention.

• Pellets cannot be removed or adjusted once inserted. If your dose is wrong, you wait 3 to 6 months for levels to drop naturally. This is a real clinical risk, not a footnote.
• The FDA has not approved any subcutaneous hormone pellet product. All pellets used in the U.S. are compounded, which means they fall outside the approval pathway that governs dosing standardization and sterility verification for brand-name drugs.
• The Endocrine Society's 2018 clinical practice guidelines for testosterone therapy do not list pellets as a preferred delivery method, in part because of the dose-adjustment problem.
• Symptom-based prescribing without baseline labs and a confirmed diagnosis is not good medicine, regardless of delivery method. If a medspa is offering pellets without comprehensive bloodwork, that is a red flag.
• Telehealth and regulated clinical platforms can offer HRT assessment with appropriate lab monitoring. The "minimal hassle" framing in this caption should not be a reason to skip that process.

The bottom line

A caption marketing pellets as a "convenient" solution with "minimal hassle" to 132,000 viewers, while the video audio plays a love song, is doing a lot of medical work with very little transparency. The claims are not fabricated, but they are selectively optimistic in ways that could lead patients toward a delivery method without understanding its specific risks. Patients deserve the full picture, not just the sales pitch.